
Episode #118
Autoimmune Diabetes: The Next Decade | Dr. Tom Elliott
About the Episode Some people diagnosed with type 2 diabetes have a slow, autoimmune form of diabetes called LADA, where the immune system attacks the cells that make insulin. Dr. Brendan Byrne and endocrinologist Dr. Tom Elliott explain how antibody testing works, what the newly approved drug teplizumab can and can't do, and why very low doses of Ozempic may help protect insulin-making cells. They also look ahead at the treatments that could arrive in the next five to ten years. About the Guest Dr. Tom Elliott is an endocrinologist at Vancouver General Hospital and a Clinical Associate Professor at the University of British Columbia, where he has been on faculty since 1992. He founded BC Diabetes in 2007, has authored 93 scientific papers, and leads research on early intervention in type 1 diabetes and diabetes technology. He also works alongside the LifestyleRx team and shares patients with the program. About The Path Podcast The Path is about simple strategies for better metabolic health. We break down metabolic disease, prediabetes, and type 2 diabetes through patient FAQs, better health decisions, and honest interviews with patients and the physicians who treat them. Learn More About LifestyleRx: https://lifestylerx.io/ Ask us a video question! https://ask-a-question.lifestylerx.ca Episode 118 | The Path Podcast

